Trials / Completed
CompletedNCT01844583
Safety, Tolerability and Pharmacokinetic (PK) of Concomitant Esomeprazole and Rifampin, and QT Study on Single and Multiple-doses of Alisertib
Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Millennium Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the drug-drug interaction (DDI) of either esomeprazole or rifampin on the single-dose PK of alisertib, and to complete an intensive QT study of single and multiple-dose alisertib.
Detailed description
The drug tested in this study is called alisertib. Alisertib is being tested to assess the effect of a proton pump inhibitor and strong metabolic inducer on the PK of a single 50 mg dose of alisertib administered as enteric-coated tablets (ECTs). The study enrolled 55 patients. Participants received either: * Esomeprazole 40 mg and Alisertib 50 mg * Rifampin 600 mg and Alisertib 50 mg All participants were asked to take one tablet of alisertib either once or twice daily in all cycles. In Cycle 2, participants were asked to take alisertib plus either esomeprazole or rifampin. This trial was conducted the United States. The overall time to participate in this study was 10 months. Participants made multiple visits to the clinic plus a final visit, 30 days after receiving their last dose of study drug for a follow-up assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alisertib | Alisertib tablets |
| DRUG | Esomeprazole | Esomeprazole capsules |
| DRUG | Rifampin | Rifampin capsules |
Timeline
- Start date
- 2013-06-25
- Primary completion
- 2014-08-04
- Completion
- 2016-09-06
- First posted
- 2013-05-01
- Last updated
- 2019-03-25
- Results posted
- 2019-03-25
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01844583. Inclusion in this directory is not an endorsement.